Michael Barbella, Managing Editor11.29.22
AccurKardia and Mawi are teaming up to integrate the former's proprietary ECG analytics into the latter’s new cardiac monitoring watch.
The Mawi Watch is a medical-grade, easy-to-use wearable for continuous cardiac health monitoring. Mawi’s device is fully smartphone-free and provides access to 24/7 patient health data gathering with up to two weeks’ battery life. With its pulse wave analysis approach, Mawi Watch tracks blood pressure continuously, passively and with no cuffs needed. Mawi Watch tracks silent AFibs, combining photoplethysmography (PPG) and ECG technologies; ECG snapshots are a diagnostic tool, while passive PPG recording makes monitoring continuous. The device also tracks core cardiac health vitals, including heart rate, blood oxygen, respiratory rate and heart rate variability (HRV). Mawi Watch comes with RPM software, which provides healthcare practitioners with real-time health data and high-risk alerts.
“Joining forces will provide our new Mawi Watch with next level ECG analytics as we create a fully integrated solution for chronic patients’ cardiac remote monitoring,” Mawi CEO Ron Fridman said. “We’re on a mission to beat the heart’s ‘silent killers’ and our new cardiac monitoring solution will empower clinicians at all stages of patient management, identifying cardiovascular issues earlier and more effectively.”
As part of the collaboration, AccurKardia’s innovation in device agnostic automated ECG analytics will complement Mawi’s expertise in designing, developing and deploying cardiac monitoring devices and wearables. This joint offering will enable the early detection of potentially life-threatening cardiovascular conditions that may be otherwise missed or diagnosed at a late stage.
“We are excited to work with Mawi, an innovative medtech player developing a new generation of cardiac monitoring devices and wearables. Both AccurKardia and Mawi have a shared goal of improving patient outcomes through remote patient monitoring solutions,” AccurKardia CEO Juan C. Jiménez said. “By equipping the next generation of wearables with automated ECG analysis capabilities, together we are raising the bar in cardiovascular health monitoring, improving access to quality care and ultimately saving lives.”
AccurKardia is a digital-first and software-only healthcare company that provides clinical-grade, device-agnostic, API-accessible automated ECG analytics to clinical and consumer-grade ECG devices, as well as telehealth and remote patient monitoring companies.
Mawi is a medtech company that brings together U.S. Food and Drug Administration/CE-cleared wearables and smart analytics software, providing healthcare professionals with a suite of cardiac monitoring tools to cover the full risk spectrum of patients—from short-term ambulatory Holter monitoring to long-term remote patient monitoring. Founded in 2017 by four Ukrainians, Mawi now successfully operates in Europe, the United States, and the Middle East, and works with more than 60 hospitals worldwide.
The Mawi Watch is a medical-grade, easy-to-use wearable for continuous cardiac health monitoring. Mawi’s device is fully smartphone-free and provides access to 24/7 patient health data gathering with up to two weeks’ battery life. With its pulse wave analysis approach, Mawi Watch tracks blood pressure continuously, passively and with no cuffs needed. Mawi Watch tracks silent AFibs, combining photoplethysmography (PPG) and ECG technologies; ECG snapshots are a diagnostic tool, while passive PPG recording makes monitoring continuous. The device also tracks core cardiac health vitals, including heart rate, blood oxygen, respiratory rate and heart rate variability (HRV). Mawi Watch comes with RPM software, which provides healthcare practitioners with real-time health data and high-risk alerts.
“Joining forces will provide our new Mawi Watch with next level ECG analytics as we create a fully integrated solution for chronic patients’ cardiac remote monitoring,” Mawi CEO Ron Fridman said. “We’re on a mission to beat the heart’s ‘silent killers’ and our new cardiac monitoring solution will empower clinicians at all stages of patient management, identifying cardiovascular issues earlier and more effectively.”
As part of the collaboration, AccurKardia’s innovation in device agnostic automated ECG analytics will complement Mawi’s expertise in designing, developing and deploying cardiac monitoring devices and wearables. This joint offering will enable the early detection of potentially life-threatening cardiovascular conditions that may be otherwise missed or diagnosed at a late stage.
“We are excited to work with Mawi, an innovative medtech player developing a new generation of cardiac monitoring devices and wearables. Both AccurKardia and Mawi have a shared goal of improving patient outcomes through remote patient monitoring solutions,” AccurKardia CEO Juan C. Jiménez said. “By equipping the next generation of wearables with automated ECG analysis capabilities, together we are raising the bar in cardiovascular health monitoring, improving access to quality care and ultimately saving lives.”
AccurKardia is a digital-first and software-only healthcare company that provides clinical-grade, device-agnostic, API-accessible automated ECG analytics to clinical and consumer-grade ECG devices, as well as telehealth and remote patient monitoring companies.
Mawi is a medtech company that brings together U.S. Food and Drug Administration/CE-cleared wearables and smart analytics software, providing healthcare professionals with a suite of cardiac monitoring tools to cover the full risk spectrum of patients—from short-term ambulatory Holter monitoring to long-term remote patient monitoring. Founded in 2017 by four Ukrainians, Mawi now successfully operates in Europe, the United States, and the Middle East, and works with more than 60 hospitals worldwide.